Drugs and the heart. IV. Antiarrhythmic agents.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000638:Amiodarone / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000145:classification / Q000627:therapeutic use*; D001073:Aprindine / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D001949:Bretylium Compounds / Q000627:therapeutic use; D004077:Digoxin / Q000627:therapeutic use; D004206:Disopyramide / Q000627:therapeutic use; D006329:Heart Conduction System / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008012:Lidocaine / Q000627:therapeutic use; D008801:Mexiletine / Q000627:therapeutic use; D011342:Procainamide / Q000627:therapeutic use; D011802:Quinidine / Q000627:therapeutic use; D014700:Verapamil / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D001949:Bretylium Compounds; D008801:Mexiletine; D001073:Aprindine; D004077:Digoxin; D008012:Lidocaine; D014700:Verapamil; D004206:Disopyramide; D011802:Quinidine; D011342:Procainamide; D000638:Amiodarone